SpliceBio

The #SpliceBio team had a great week in Rome at the #ESGCT Annual Congress 2024!    Sílvia Frutos, PhD, co-founder and CTO and Izarbe Aísa Marín, PhD, Scientist, attended the key industry event organised by European Society of Gene and Cell Therapy. The team joined insightful sessions and enjoyed networking with fellow cell and #genetherapy specialists!   Get in touch to discover more about SpliceBio's next generation gene therapy programs, including lead program, SB007, targeting #Stargardtdisease.   #ESGCT2024 #biotech #retinaldiseases #lifesciences #ProteinSplicing #ophthalmology

#SpliceBio's clinical team will be in Chicago for the American Academy of Ophthalmology Annual Meeting 2024 this week!   📅 The Academy's annual meeting is taking place from 18th-21st October, where ophthalmology clinicians will gather to discover the latest advancements, gain insights from experts, and network with the global #ophthalmology community.   SpliceBio's clinical team, led by our CMO, Aniz Girach, will be in attendance to provide insights into SpliceBio's next-generation gene therapy programs aimed at treating genetic diseases, including its lead program, SB007, targeting #Stargardtdisease, the most common inherited retinal disorder. Get in touch to arrange a meeting!   #biotech #retinaldiseases #lifesciences #ProteinSplicing #AAO2024

Did you miss Drug Discovery World's webinar featuring our CBO, Gerard Caelles? Watch the webinar on demand to explore, 'What are the challenges and advancements driving Cell and Gene Therapy (#CGT) drug development?'   📽 Click the link to discover key trends, opportunities and challenges in the #genetherapy sector, and watch Gerard's presentation on #SpliceBio's cutting-edge #ProteinSplicing platform and next generation gene therapies, including lead program, SB007, targeting #Stargardtdisease.   https://lnkd.in/eZJ2xhu4   #biotech #retinaldiseases #lifesciences #ProteinSplicing #ophthalmology

🎧 Listen to Optimum Strategic Communications' podcast published today to celebrate progress in #opthalmology research for World Sight Day! The podcast features #SpliceBio's Senior Director of Clinical Development, Feride Sahin, who shares her insights on recent advancements in the field and the importance of protecting our eyes and vision.   We are proud to be contributing to discovering treatments for inherited retinal disorders and working towards developing life-changing therapies for patients in need with our proprietary #ProteinSplicing platform, including lead program, SB007, targeting #Stargardtdisease. Find out more below ⬇   #biotech #retinaldiseases #lifesciences #ProteinSplicing #opthalmology

Meet #SpliceBio in Phoenix, Arizona! Our CBO, Gerard Caelles, is joining industry leaders in cell and #genetherapy, gene editing, and tissue engineering for the sector's premier conference, the Cell & Gene Meeting on the Mesa being held on the 7-9 October!   📅 Get in touch to arrange a meeting at the event and learn more about our next-generation gene therapies and lead program, SB007, targeting #Stargardtdisease.   We look forward to connecting with other attendees at the conference!   #biotech #retinaldiseases #lifesciences #ProteinSplicing #opthalmology #CGMesa24

📽 Tune in to watch our CBO, Gerard Caelles, as he joins Drug Discovery World's 'What are the challenges and advancements driving Cell and Gene Therapy (CGT) drug development?' in an online webinar on 8 October at 15.00pm BST!   Gerard will be providing insights into #SpliceBio's cutting-edge #ProteinSplicing platform, designed to tackle diseases that have remained elusive to conventional genetic therapies, and delving into what the future holds for the CGT space!   Register here free to secure your place: https://lnkd.in/e6A4Zqbg and do get in touch 💡if you have any questions about SpliceBio's next generation gene therapies and its lead program, SB007, targeting #Stargardtdisease, a genetic eye disease that causes vision loss in children and adults.   #biotech #retinaldiseases #lifesciences #ProteinSplicing #opthalmology

🎥📰 Our co-founder and CEO Miquel Vila-Perello spoke yesterday with Brad Loncar of BiotechTV in our headquarters in Barcelona about SpliceBio's Protein Splicing platform, our next-gen approach to gene therapy and the progress with our lead program SB007 in Stargardt disease. Thank you for Brad Loncar for stepping by our offices and labs at the Parc Científic de Barcelona and look forward to hosting you again soon! Full video: https://lnkd.in/g49sphf3 #GeneTherapy #Stargardtdisease #IRD #ProteinSplicing

📅 #SpliceBio is attending the 24th European Society of Retina Specialists (EURETINA) Congress from the 19-22 September in Barcelona, Spain!   Make sure to reach out to the team to schedule a meeting, where retina experts will come together to share insights and progress in retina science with the aim of preventing avoidable blindness.   Follow SpliceBio to learn more about its next generation gene therapies and lead program targeting #Stargardtdisease, a genetic eye disease that causes vision loss in children and adults.   #biotech #retinaldiseases #lifesciences #ProteinSplicing #opthalmology #EURETINA24

🎺 We are excited to announce that we have been shortlisted as a finalist at Citeline's #ScripAwards2024 in the 'Quris-AI Best Partnership Alliance Award’ category for our collaboration with Spark Therapeutics, Inc.! 🎉 We are honoured to be shortlisted amongst our fellow finalists for our partnership with Spark Therapeutics to develop a novel #genetherapy targeting an inherited #retinaldisease. We would like to thank and congratulate the #SpliceBio team for their continued dedication towards developing life-changing #genetherapies. Winners will be announced at the awards ceremony on 4th December in London!   #biotech #retinaldiseases #lifesciences #ProteinSplicing #Stargardtdisease

June 13th marks Rare Chromosome & Gene Disorder Awareness Day, a day which aims to raise awareness and encourage a greater understanding of rare chromosome and gene disorders amongst all.   Join us in raising awareness about the daily challenges faced by those affected, and their families, by unique genetic variations.   At #SpliceBio, we are focused on developing life-changing #genetherapies using our proprietary #ProteinSplicing platform which offers the potential to address diseases that currently cannot be treated with gene therapies, due to the necessary gene being too large to be delivered by adeno-associated virus (AAV) vectors.   Our lead program, SB007 targets #Stargardtdisease, a genetic eye disease that causes vision loss in children and adults. Stargardt disease is the most common inherited retinal disorder, affecting 1 in 8,000 to 10,000 people.   #biotech #retinaldiseases #lifesciences #genetherapy #rarechromoday #shinebrighttogether